2026-09-21T01:07:10Zhttps://dspace.mit.edu/server/oai/request

oai:dspace.mit.edu:1721.1/684692022-01-13T07:53:45Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023

Fiona Murray and Andrew W. Lo. Wagner, Alice Elizabeth, 1980- Harvard University--MIT Division of Health Sciences and Technology. Harvard University--MIT Division of Health Sciences and Technology 2012-01-12T19:30:14Z 2012-01-12T19:30:14Z 2011 2011 http://hdl.handle.net/1721.1/68469 769908949 Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2011. Cataloged from PDF version of thesis. "Pages 65-70 contain illegible text. This is the best copy available"--P. after t.p. Includes bibliographical references (p. 63-64). Investors have difficulty funding the life sciences because of the high risks involved in research and development and commercialization of new products. Risk in the biopharmaceutical industry is the result of scientific, regulatory and economic uncertainty. The nature of the biopharmaceutical industry introduces many challenges. Each of these challenges incorporates a measure of risk into drug development. The level of understanding of technical success interdependencies has not been fully investigated. These interdependencies (correlations) could lead to an overall greater risk to the company's portfolio than previously expected. A better understanding of the risks that lead to success or failure in drug development might encourage more investment in the life sciences and specifically in the biopharmaceutical industry, and a greater awareness of the correlations between risks and products might lead to more informed decision making on a biopharmaceutical portfolio leading increased productivity. A dataset was collected from Thomson Reuters. The dataset is the oncology portfolio from a biopharmaceutical company, Genentech Inc. Logistic regression was used to determine if any of the defined variables contributed to the success or failure of the oncology products. The chi-square value was 7.738 with the degrees of freedom equal to 5 and with a p-value of 0.17. Therefore, none of the variables significantly contributed to the outcome. More research should be performed in this area in order to better understand the risk in a biopharmaceutical portfolio. by Alice Elizabeth Wagner. S.M. 74 p. eng Massachusetts Institute of Technology M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 Harvard University--MIT Division of Health Sciences and Technology. Understanding risk in a biopharmaceutical portfolio Thesis application/pdf false Publication unknown unknown <Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="77d4e722-ebd8-4748-ac7c-eb319b3281de"> <Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type> <Language>eng</Language> <Title>Understanding risk in a biopharmaceutical portfolio</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2011</PublicationDate> <Authors> <Author> <DisplayName>Wagner, Alice Elizabeth, 1980-</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <DisplayName>Massachusetts Institute of Technology</DisplayName> <OrgUnit /> </Publisher> </Publishers> <License>http://dspace.mit.edu/handle/1721.1/7582</License> <Keyword>Harvard University--MIT Division of Health Sciences and Technology.</Keyword> <Abstract>Investors have difficulty funding the life sciences because of the high risks involved in research and development and commercialization of new products. Risk in the biopharmaceutical industry is the result of scientific, regulatory and economic uncertainty. The nature of the biopharmaceutical industry introduces many challenges. Each of these challenges incorporates a measure of risk into drug development. The level of understanding of technical success interdependencies has not been fully investigated. These interdependencies (correlations) could lead to an overall greater risk to the company&apos;s portfolio than previously expected. A better understanding of the risks that lead to success or failure in drug development might encourage more investment in the life sciences and specifically in the biopharmaceutical industry, and a greater awareness of the correlations between risks and products might lead to more informed decision making on a biopharmaceutical portfolio leading increased productivity. A dataset was collected from Thomson Reuters. The dataset is the oncology portfolio from a biopharmaceutical company, Genentech Inc. Logistic regression was used to determine if any of the defined variables contributed to the success or failure of the oncology products. The chi-square value was 7.738 with the degrees of freedom equal to 5 and with a p-value of 0.17. Therefore, none of the variables significantly contributed to the outcome. More research should be performed in this area in order to better understand the risk in a biopharmaceutical portfolio.</Abstract> <Access xmlns="http://purl.org/coar/access_right" > </Access> </Publication>